Skip to content

What drugs in latest cancelled study?

Page last modified on: November 20, 2008
Question from Ninnj: What drugs were in the latest study that was canceled?
Answer —Generosa Grana, M.D., F.A.C.P.: There has been a study in the planning stages for women with increased risk of breast cancer comparing Evista (chemical name: raloxifene) to letrozole. While tremendous enthusiasm surrounded this study, and it was a continuation of much work that has been invested in prevention of breast cancer, the NCI has not seen fit to fund the trial. Currently, other sources of funding are being sought and we will yet have to see if this trial will go forward. There is going to be data on the use of aromatase inhibitors in the prevention setting. A trial currently being done in Europe, IDIS II, will give us such information. As of yet, the only drug FDA-approved for prevention is tamoxifen. There is data (although no FDA approval) for Evista in post-menopausal women. And there is no data on the aromatase inhibitors in a prevention setting.

On Wednesday, June 20, 2007, the Ask-the-Expert Online Conference was called Updates from the 2008 ASCO Annual Meeting. Generosa Grana, M.D., F.A.C.P. and moderator Nicholas Robert, M.D. answered your questions about the latest news on breast cancer screening, treatment, and side effects reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Together we can make a difference

Email Updates

Stay informed about current research, online events, and more.

Please leave this field empty

Meet the Experts

Generosa Grana, M.D., F.A.C.PGenerosa Grana, M.D., F.A.C.P. is the director of the Cooper Cancer Institute and heads the division of hematology/medical oncology at Cooper University Hospital.

Nicholas Robert, M.D.Nicholas Robert, M.D. is a co-chair of the Breast Committee of the U.S. Oncology Research Network and also chairs the Cancer Committee and Research Committee of the Inova Fairfax Hospital's Cancer Center. 

Back to top

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

Learn more about our commitment to your privacy

© 2010 Breastcancer.org - All rights reserved.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.